These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23377200)

  • 21. Concomitant Methotrexate Protects Against Total Knee Arthroplasty in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Asai S; Takahashi N; Funahashi K; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
    J Rheumatol; 2015 Dec; 42(12):2255-60. PubMed ID: 26428206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
    Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
    Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semi-quantitative analysis of
    Ravikanth R; Singh JK
    World J Nucl Med; 2020; 19(4):347-352. PubMed ID: 33623503
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Occupational therapy in rheumatoid arthritis: short term prospective study in patients treated with anti-TNF-alpha drugs].
    Pasqui F; Mastrodonato L; Ceccarelli F; Scrivo R; Magrini L; Riccieri V; Di Franco M; Gentili M; Valesini G; Spadaro A
    Reumatismo; 2006; 58(3):191-8. PubMed ID: 17013435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission.
    Son KM; Song SH; Lim SK; Seo YI; Kim HA
    Clin Exp Rheumatol; 2012; 30(6):947-50. PubMed ID: 22935437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joint tenderness and swelling in biologic-treated inflammatory arthritis patients - a tricky trade off?
    Harty LC; Ng CT; Fearon C; Murray CA; Fitzgerald O; Veale DJ
    Int J Clin Pract; 2012 Feb; 66(2):128-31. PubMed ID: 22257038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study.
    Ellegaard K; Christensen R; Torp-Pedersen S; Terslev L; Holm CC; Kønig MJ; Jensen PS; Danneskiold-Samsøe B; Bliddal H
    Rheumatology (Oxford); 2011 Mar; 50(3):506-12. PubMed ID: 21071479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
    Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
    PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Methods of efficacy assessment of the knee joint radiosynoviorthesis- personal experience].
    Zwolak R; Majdan M
    Wiad Lek; 2018; 71(1 pt 1):10-16. PubMed ID: 29558346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
    Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
    Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictor of Hand Radiological Progression in Patients With Rheumatoid Arthritis Receiving TNF Antagonist Therapy by Change in Grayscale Synovitis-A Preliminary Study.
    Chen YC; Su FM; Hsu SW; Chen JF; Cheng TT; Lai HM; Chiu WC
    J Clin Rheumatol; 2017 Mar; 23(2):73-76. PubMed ID: 28212115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural joint damage and hand bone loss in patients with rheumatoid arthritis.
    Ørnbjerg LM
    Dan Med J; 2018 Mar; 65(3):. PubMed ID: 29510810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.